APTO logo

Aptose Biosciences (APTO) Company Overview

Profile

Full Name:

Aptose Biosciences Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

March 16, 1992

Indexes:

Not included

Description:

Aptose Biosciences is a biotechnology company focused on developing innovative cancer therapies. They create targeted treatments to improve patient outcomes, particularly for blood cancers. Their research aims to address unmet medical needs and advance personalized medicine in oncology.

Events Calendar

Earnings

Next earnings date:

Mar 26, 2025

Recent quarterly earnings:

Nov 8, 2024

Recent annual earnings:

Mar 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Feb 26, 2025

Analyst ratings

Recent major analysts updates

Feb 12, 25 HC Wainwright & Co.
Buy
Jan 10, 25 HC Wainwright & Co.
Buy
Dec 10, 24 HC Wainwright & Co.
Buy
Dec 3, 24 HC Wainwright & Co.
Buy
Nov 20, 24 HC Wainwright & Co.
Buy
Aug 11, 23 RBC Capital
Outperform
Aug 11, 23 Piper Sandler
Overweight
Aug 11, 23 Oppenheimer
Outperform
Aug 11, 23 HC Wainwright & Co.
Buy
Jun 12, 23 Oppenheimer
Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Aptose Biosciences?
  • Does Aptose Biosciences pay dividends?
  • What sector is Aptose Biosciences in?
  • What industry is Aptose Biosciences in?
  • What country is Aptose Biosciences based in?
  • When did Aptose Biosciences go public?
  • Is Aptose Biosciences in the S&P 500?
  • Is Aptose Biosciences in the NASDAQ 100?
  • Is Aptose Biosciences in the Dow Jones?
  • When was Aptose Biosciences's last earnings report?
  • When does Aptose Biosciences report earnings?
  • Should I buy Aptose Biosciences stock now?

What is the ticker symbol for Aptose Biosciences?

The ticker symbol for Aptose Biosciences is NASDAQ:APTO

Does Aptose Biosciences pay dividends?

No, Aptose Biosciences does not pay dividends

What sector is Aptose Biosciences in?

Aptose Biosciences is in the Healthcare sector

What industry is Aptose Biosciences in?

Aptose Biosciences is in the Biotechnology industry

What country is Aptose Biosciences based in?

Aptose Biosciences is headquartered in Canada

When did Aptose Biosciences go public?

Aptose Biosciences's initial public offering (IPO) was on March 16, 1992

Is Aptose Biosciences in the S&P 500?

No, Aptose Biosciences is not included in the S&P 500 index

Is Aptose Biosciences in the NASDAQ 100?

No, Aptose Biosciences is not included in the NASDAQ 100 index

Is Aptose Biosciences in the Dow Jones?

No, Aptose Biosciences is not included in the Dow Jones index

When was Aptose Biosciences's last earnings report?

Aptose Biosciences's most recent earnings report was on Nov 8, 2024

When does Aptose Biosciences report earnings?

The next expected earnings date for Aptose Biosciences is Mar 26, 2025

Should I buy Aptose Biosciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions